drugset / Trial / NCT01361802

Ambroxol Spray Sore Throat Study

NCT01361802

Phase 2 Completed 494 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The development of a new Ambroxol spray formulation for the treatment of sore throat pain associated with acute pharyngitis requires an initial phase II study to be conducted in order to select the most appropriate dose for pain relief.

Timeline

Start
2011-05
Primary completion
2011-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ambroxol Small molecule 2.5 mg
Comparator Ambroxol Small molecule 5 mg
Comparator Ambroxol Small molecule 10 mg

Indications